30 September 2020 —
After attending this symposium, participants should be able to:
- Review the current management strategies for metastatic hormone-sensitive prostate cancer (mHSPC) to optimise patient care
- Discuss the impact of new data on treatment and management decisions forindividual patients with non-metastatic castration-resistant prostate cancer(nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC)
- Describe considerations ...